| Ytd | 78.06% | |
| 1y | 69.34% |
| Open | 36.99 | Prev Close | 37.34 | Low | 35.23 | High | 37.59 | Mkt Cap | 579.63M |
| Vol | 226.63K | Avg Vol | 210.85K | EPS | -4.55 | P/E | -8.06 | Forward P/E | -4.85 |
| Beta | 1.68 | Short Ratio | 7.15 | Inst. Own | 110.72% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 31.52 | 200-d Avg | 24.94 | 1yr Est | 52.80 |
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medici
Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medici
47 total developmental milestones gained across 10 participants, with durable treatment effect and n
U.S. stock futures lower, Dow futures down 1%. Yatsen Holding shares fall 10.1%, while other stocks
Autodesk Inc (ADSK) rose sharply after beating Q4 earnings & issuing strong guidance. Other gain